An observational study in Covid-19 and Lung Cancer, sponsored by Spanish Lung Cancer Group. Completed at 75 sites in Spain. Per ClinicalTrials.gov, last updated 2022-06-27.
Sponsored by Spanish Lung Cancer Group · Observational
This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members.
The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 886 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Spanish Lung Cancer Group is the lead sponsor of 22 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with lung cancer and who have been infected with COVID-19.
Exclusion Criteria:
lung cancer patients diagnosed with COVID-19
Clinical data of lung cancer patients with COVID-19 diagnoses
Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
Diagnosis data
Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis
Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
Treatments received
Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received
Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
Prognostic factors
Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.
Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spanish Lung Cancer Group